![]() ![]() ![]() However, in the United States, the sofosbuvir–daclatasvir regimen has fallen out of favor given inferior response rates in non–head-to-head comparisons with other regimens in registration trials ( 6). ![]() The WHO defines pangenotypic treatment regimens as those achieving a rate of sustained virologic response (SVR) greater than 85% across all major HCV genotypes ( 3). clinicians the opportunity to simplify and reduce the cost of care without compromising care quality. This differs from guidance from the American Association for the Study of Liver Diseases and Infectious Diseases Society of America ( 4, 5), which recommends specific DAA treatment regimens based on genotype and more intensive laboratory testing before and during treatment. The WHO recommends pangenotypic regimens that simplify pretreatment and on-treatment testing. In current treatment regimens, combination therapy with oral DAAs has replaced interferon and ribavirin. The WHO recommends offering treatment to all persons older than 12 years who have chronic HCV infection, and it notes 3 major considerations for this “treat all” strategy: the effectiveness and safety of direct-acting antiviral agents (DAAs), the emergence of pangenotypic drug regimens, and reduction in the cost of treatment ( 3). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |